AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

PROTEOME SCIENCES PLC

Report Publication Announcement Mar 28, 2018

7860_rns_2018-03-28_0a2e9502-f6f7-4115-b0d3-9550c3bf1685.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1658J

Proteome Sciences PLC

28 March 2018

29 March 2018

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Notice of Results

The Directors look forward to updating shareholders on the Company's performance, and on the outlook for 2018, at the time we announce our 2017 full year results which are scheduled for release on 24 April 2018. 

Annual General Meeting

The Annual General Meeting will take place in London during the last week of May 2018 and further details will be provided in due course.

For further information:

Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Ian Pike, Chief Scientific Officer
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/James Thompson

Abigail Wayne (Broking)
Tel: +44 (0)20 7220 0500

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLIFFEVSITFIT

Talk to a Data Expert

Have a question? We'll get back to you promptly.